Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | LCAT | P04180 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 3/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.38 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | HTR1F | P30939 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22324940 | 0.84 | TLR9 (0.41) | TLR9 | |
| SCHEMBL22324868 | 0.83 | DRD2 (0.49) | GRM2 | |
| SCHEMBL22324798 | 0.80 | SLC18A3 (0.41) | — | |
| SCHEMBL22324896 | 0.80 | SLC18A3 (0.41) | — | |
| SCHEMBL22324847 | 0.79 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3LCAT | |
| SCHEMBL22340524 | 0.77 | GRM2 (0.35) | TLR9GRM2 | |
| SCHEMBL22324860 | 0.77 | DRD2 (0.44) | — | |
| SCHEMBL22324937 | 0.77 | FAAH (0.42) | GRM2 | |
| SCHEMBL167849 | 0.77 | TRPV6 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3TRPV6 | |
| SCHEMBL22340466 | 0.76 | DHFR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | CHRNB2 1365/4885CHRNA4 727/4885CHRNB4 574/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | CHRNB2 1365/4885CHRNA4 727/4885CHRNB4 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.